Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Operating Margin (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Operating Margin for 6 consecutive years, with 758.68% as the latest value for Q3 2025.

  • On a quarterly basis, Operating Margin fell 77754.0% to 758.68% in Q3 2025 year-over-year; TTM through Sep 2025 was 245.89%, a 10319.0% decrease, with the full-year FY2024 number at 129.18%, up 35135.0% from a year prior.
  • Operating Margin was 758.68% for Q3 2025 at Ensysce Biosciences, down from 127.64% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 18.86% in Q3 2024 to a low of 3400.56% in Q2 2022.
  • A 5-year average of 719.09% and a median of 467.7% in 2023 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: crashed -330774bps in 2022, then surged 293286bps in 2023.
  • Ensysce Biosciences' Operating Margin stood at 122.71% in 2021, then plummeted by -253bps to 432.57% in 2022, then tumbled by -42bps to 612.72% in 2023, then surged by 55bps to 274.34% in 2024, then plummeted by -177bps to 758.68% in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Operating Margin are 758.68% (Q3 2025), 127.64% (Q2 2025), and 149.08% (Q1 2025).